Back to Search Start Over

Pulmonary Rehabilitation Associated with Noninvasive Ventilation on Physical Capacity and Quality of Life in Post-COVID-19: A Randomized Controlled Double-Blinded Clinical Trial Protocol.

Authors :
Arêas GPT
Goulart CDL
Sant'Anna T
Fernandes TG
Alvim RO
Borges FFDR
do Amaral CMSSB
Rodrigues SCF
Valente J
Ferreira JMBB
Rezende AG
de Oliveira Júnior EF
de Lacerda MVG
de Almeida-Val FF
Source :
Journal of multidisciplinary healthcare [J Multidiscip Healthc] 2024 Apr 05; Vol. 17, pp. 1483-1490. Date of Electronic Publication: 2024 Apr 05 (Print Publication: 2024).
Publication Year :
2024

Abstract

Background: The coronavirus disease-2019 (COVID-19) pulmonary rehabilitation (PR) seems to be a better choice to improve physical and functional capacity after acute infection. However, there is a lack of evidence regarding the effects of different strategies to optimize post-acute phase rehabilitation and reduce long COVID-19 physical deteriorations.<br />Objective: To compare the use of a noninvasive ventilation (NIV) plus aerobic exercise strategy during PR program with to a standard PR (without NIV) on physical capacity and quality of life outcomes in post-COVID-19.<br />Methods: Double-blinded randomized controlled clinical trial. A total of 100 individuals discharged from hospital in a post-acute phase of severe COVID-19 will be randomized into two groups: PR + NIV (Group 1) and PR (Group 2). Inclusion criteria include participants who present symptomatic dyspnea II and III by the modified Medical Research Council, aged 18 years or older. Both groups will receive aerobic and resistance exercise, and inspiratory muscle training. However, group 1 will perform aerobic training with bilevel NIV. Cardiopulmonary exercise test will assess the O <subscript>2</subscript> peak uptake, 6-minute walk test will assess the walking distance and short-form 36 will assess the quality of life before and after 8 weeks (after 24 PR sessions). Moreover, patients will be contacted by telephone every 3 months for one year to record possible adverse events, hospitalizations, and death. All data will be registered in RedCap, and analyses will be performed in the STATA v13 software.<br />Clinical Trial Registration: RBR-3t9pkzt.<br />Competing Interests: The authors have no conflicts to disclose.<br /> (© 2024 Arêas et al.)

Details

Language :
English
ISSN :
1178-2390
Volume :
17
Database :
MEDLINE
Journal :
Journal of multidisciplinary healthcare
Publication Type :
Academic Journal
Accession number :
38596000
Full Text :
https://doi.org/10.2147/JMDH.S438120